U.S. Markets closed

Regulus Therapeutics enters amended agreement with Biogen

Regulus Therapeutics (RGLS) disclosed that the company and Biogen (BIIB) entered into an amendment to the collaboration and license agreement dated August 15, 2012 between the company and Biogen. The amendment provides for, among other things, revised terms with respect to phase 1 of the research plan under the agreement and revised payment provisions relating to the phase 1 milestones. The amendment does not modify the maximum dollar amount the company was originally eligible to receive in connection with phase 1 milestones under the agreement.